Marksans Pharma Limited (MARKSANS.NS)
INR 211.44
(-0.97%)
INR 211.44
(-0.97%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 6.17 Billion INR | 27.48% |
| 2022 | 4.84 Billion INR | 14.21% |
| 2021 | 4.24 Billion INR | 4.98% |
| 2020 | 4.04 Billion INR | 67.18% |
| 2019 | 2.41 Billion INR | -17.53% |
| 2018 | 2.93 Billion INR | 34.44% |
| 2017 | 2.18 Billion INR | 14.75% |
| 2016 | 1.9 Billion INR | 13.29% |
| 2015 | 1.67 Billion INR | 28.96% |
| 2014 | 1.3 Billion INR | 26.82% |
| 2013 | 1.02 Billion INR | 32.05% |
| 2012 | 776.91 Million INR | 5.91% |
| 2011 | 733.58 Million INR | 9.14% |
| 2010 | 672.18 Million INR | -35.69% |
| 2009 | 1.04 Billion INR | -12.22% |
| 2008 | 1.19 Billion INR | -14.6% |
| 2007 | 1.39 Billion INR | 12.5% |
| 2006 | 1.23 Billion INR | 57.06% |
| 2005 | 789.07 Million INR | 50.54% |
| 2004 | 524.15 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 6.17 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 5.3 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 6.17 Billion INR | 27.48% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 4.27 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 4.84 Billion INR | 0.0% |
| 2022 FY | 4.84 Billion INR | 14.21% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 4.24 Billion INR | 4.98% |
| 2021 Q4 | 4.24 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 4 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 2.76 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 4.04 Billion INR | 0.0% |
| 2020 FY | 4.04 Billion INR | 67.18% |
| 2019 Q4 | 2.41 Billion INR | 0.0% |
| 2019 Q2 | 2.34 Billion INR | 0.0% |
| 2019 FY | 2.41 Billion INR | -17.53% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 2.93 Billion INR | 0.0% |
| 2018 FY | 2.93 Billion INR | 34.44% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 2.37 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 2.18 Billion INR | 14.75% |
| 2017 Q4 | 2.18 Billion INR | 0.0% |
| 2017 Q2 | 1.87 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 1.9 Billion INR | 0.0% |
| 2016 Q2 | 1.74 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 1.9 Billion INR | 13.29% |
| 2015 Q2 | 1.48 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 1.67 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 1.67 Billion INR | 28.96% |
| 2014 Q2 | 1.14 Billion INR | 0.0% |
| 2014 FY | 1.3 Billion INR | 26.82% |
| 2014 Q4 | 1.3 Billion INR | 20.78% |
| 2014 Q3 | 1.07 Billion INR | -5.75% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 1.02 Billion INR | 32.05% |
| 2013 Q4 | 1.02 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 1.04 Billion INR | 0.0% |
| 2012 FY | 776.91 Million INR | 5.91% |
| 2012 Q4 | 776.91 Million INR | 0.0% |
| 2012 Q2 | 1.49 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 FY | 733.58 Million INR | 9.14% |
| 2010 FY | 672.18 Million INR | -35.69% |
| 2009 FY | 1.04 Billion INR | -12.22% |
| 2008 FY | 1.19 Billion INR | -14.6% |
| 2007 FY | 1.39 Billion INR | 12.5% |
| 2006 FY | 1.23 Billion INR | 57.06% |
| 2005 FY | 789.07 Million INR | 50.54% |
| 2004 FY | 524.15 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Abbott India Limited | 6.19 Billion INR | 0.264% |
| Cipla Limited | 52.37 Billion INR | 88.203% |
| Gland Pharma Limited | 16.55 Billion INR | 62.667% |
| GlaxoSmithKline Pharmaceuticals Limited | 5.33 Billion INR | -15.739% |
| Kopran Limited | 1.38 Billion INR | -346.213% |
| NGL Fine-Chem Limited | 433.03 Million INR | -1327.01% |
| Pfizer Limited | 4.33 Billion INR | -42.485% |
| Sanofi India Limited | 6.63 Billion INR | 6.908% |
| SMS Pharmaceuticals Limited | 2.33 Billion INR | -164.42% |
| TTK Healthcare Limited | 969.89 Million INR | -537.123% |